Suresh Kumar Balasubramanian, MD
Internal Medicine · Cleveland, OHNPI 1932464294
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 65.2% of it on its own, with 15 other manufacturers making up the rest. Among internal medicine clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $1183.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$96K
- Geron Corporation$33K
- Servier Pharmaceuticals LLC$10K
- Syndax Pharmaceuticals, Inc.$4K
- Daiichi Sankyo Inc.$2K
- Gilead$2K
- plus $1K from 10 others
Across 6 payments — averaging $15,807 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$74K
- Gilead$21K
What the payments were for
- Consulting fees$62,89142%
- Speaking & faculty fees$68,65046%
- Travel & lodging$12,9919%
- Food & beverage$2,9162%
- Education$5470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 73 | $96,452 |
| Geron Corporation | 23 | $32,871 |
| Servier Pharmaceuticals LLC | 7 | $10,191 |
| Syndax Pharmaceuticals, Inc. | 5 | $3,722 |
| Daiichi Sankyo Inc. | 2 | $1,880 |
| Gilead(2 entities) | 2 | $1,626 |
| Astellas Pharma US Inc | 3 | $293 |
| Novartis | 2 | $243 |
| Genentech, Inc. | 1 | $177 |
| GSK | 1 | $111 |
| Amgen | 1 | $100 |
| Genentech USA, Inc. | 1 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $79 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Lilly USA, LLC | 1 | $41 |
| Apellis Pharmaceuticals, Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$147,995 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IdhifaEnasidenib Mesylate | 12 | $360,777 |
| RevlimidLenalidomide | 18 | $293,039 |
| Imatinib Mesylate | 12 | $46,537 |
| Acyclovir | 18 | $339 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Cleveland
- Cyrus HarrisCleveland$726K
- Marina MagreyCleveland$312K
- Joshua LonginowCleveland$241K
- Emad MansoorCleveland$219K
- Syed BukhariCleveland$165K
- Vadim KoshkinCleveland$159K
- Christine Tanaka-EspositoCleveland$123K
- Carla HarwellCleveland$75K
- Amr MohamedCleveland$72K
- Adriano TonelliCleveland$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.